OX40 controls functionally different T cell subsets and their resistance to depletion therapy

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 5584-5591

  Kroemer, Alexander ^a   Xiao, Xiang ^a   Minh, Diem Vu ^a   Gao, Wenda ^a   Minamimura, Keisuke ^a   Chen, Ming ^a   Maki, Takashi ^a   Li, Xian Chang ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; LYMPHOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; TNFRSF4 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CELL SURVIVAL; CONGENIC STRAIN; CONTROLLED STUDY; EFFECTOR CELL; FUNCTIONAL STATUS; GRAFT REJECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SKIN ALLOGRAFT; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; CYTOLOGY; DBA MOUSE; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; INNATE IMMUNITY; LYMPHOCYTE DEPLETION; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; REPORTER GENE; SKIN TRANSPLANTATION; TRANSGENIC MOUSE;

ANIMALS; ANTILYMPHOCYTE SERUM; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; FORKHEAD TRANSCRIPTION FACTORS; GENES, REPORTER; GRAFT REJECTION; IMMUNITY, NATURAL; IMMUNOPHENOTYPING; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, OX40; SKIN TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 38449117447     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.5584     Document Type: Article

References (30)

1. Warrens, A. N., G. Lombardi, and R. I. Lechler. 1994. Presentation and recognition of major and minor histocompatibility antigens. Transplant. Immunol. 2: 103-107.
2. Suchin, E. J., P. B. Langmuir, E. Palmer, M. H. Sayegh, A. D. Wells, and L. A. Turka. 2001. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166: 973-981.
3. Li, X. C., T. B. Strom, L. A. Turka, and A. D. Wells. 2001. T cell death and transplantation tolerance. Immunity 14: 407-416.
4. Knechtle, S., J. H. Fechner, Y. Dong, S. Stavrou, D. M. Neville, T. Oberley, P. Buckley, N. N. Armstrong, K. Rusterholz, X. Hong, et al. 1998. Primate renal transplants using immunotoxin. Surgery 124: 438-446.
5. Calne, R. Y., P. Friend, S. Moffatt, A. Bradley, D. A. Hale, J. Firth, J. A. Bradley, K. Smith, and H. Waldmann. 1998. Prope tolerance, perioperative campath 1H, and low dose of cyclosporin monotherapy in renal allograft recipients. Lancet 351: 1701-1702.
6. Knechtle, S., J. D. Pirsch, J. H. Fechner, B. N. Becker, A. Friedl, R. B. Colvin, L. K. Lebeck, L. T. Chin, Y. T. Becker, J. S. Odorico, et al. 2003. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J. Transplant. 3: 643-645.
7. Wu, Z., S. Bensinger, J. Zhang, C. Chen, X. Yuan, X. Huang, J. Markmann, A. Kassaee, B. R. Rosengard, W. W. Hancock, et al. 2004. Homeostatic proliferation is a barrier to transplantation tolerance. Nat. Med. 10: 21-23.
8. + regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J. Immunol. 176: 4125-4132.
9. Pearl, J. P., J. Parris, D. A. Hale, S. C. Hoffmann, W. B. Bernstein, K. L. McCoy, S. J. Swanson, R. B. Mannon, M. Roederer, and A. D. Kirk. 2005. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am. J. Transplant. 5: 465-474.
10. Maki, T., T. Ichikawa, R. Blanco, and J. Porter. 1992. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc. Natl. Acad. Sci. USA 89: 3434-3438.
11. Ogawa, N., J. F. List, J. F. Habener, and T. Maki. 2004. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53: 1700-1705.
12. Pippig, S. D., C. Pena-Rossi, J. Long, W. R. Godfrey, D. J. Fowell, S. L. Reiner, M. L. Birkeland, R. M. Locksley, A. N. Barclay, and N. Killeen. 1999. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J. Immunol. 163: 6520-6529.
13. Takeda, I., S. Ine, N. Killeen, L. C. Ndhlovu, K. Murata, S. Satomi, K. Sugamura, and N. Ishii. 2004. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 172: 3580-3589.
14. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory cells. Nature 441: 235-238.
15. Li, X. C., G. Demirci, S. F. Lacraz, C. Groves, A. Coyle, T. R. Malek, and T. B. Strom. 2001. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. 7: 114-118.
16. Yu, G., X. Xu, M. D. Vu, E. D. Kilpatrick, and X. C. Li. 2006. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J. Exp. Med. 203: 1851-1858.
17. Prell, R. A., D. E. Evans, C. Thalhofer, T. Shi, C. Funatake, and A. D. Weinberg. 2003. OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. J. Immunol. 171: 5997-6005.
18. Sugamura, K., N. Ishii, and A. D. Weinberg. 2004. Therapeutic targeting of the effector T cell costimulatory molecule OX40. Nat. Rev. Immunol 4: 420-431.
19. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T cell immunity? Nat. Rev. Immunol. 3: 609-620.
20. + TREGS. Blood In press.
21. +Foxp3+ T cells. J. Immunol. 179: 1427-1430.
22. Neujahr, D. C., C. Chen, X. Huang, J. F. Markmann, S. Cobbold, H. Waldmann, M. H. Sayegh, W. W. Hancock, and L. A. Turka. 2006. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J. Immunol. 176: 4632-4639.
23. Calderhead, D. M., J. E. Buhlmann, A. J. van den Eertwegh, E. Claassen, R. J. Noelle, and H. P. Fell. 1993. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J. Immunol. 151: 5261-5271.
24. Song, J., S. Salek-Ardakani, P. R. Rogers, M. Cheng, L. Van Parijs, and M. Croft. 2004. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat. Immunol. 5: 150-158.
25. Rogers, P. R., J. Song, I. Gramaglia, N. Killeen, and M. Croft. 2001. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15: 445-455.
26. Vu, M. D., M. R. Clarkson, H. Yagita, L. A. Turka, M. H. Sayegh, and X. C. Li. 2006. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J. Immunol. 176: 1394-1401.
27. Salek-Ardakani, S., J. Song, B. S. Halteman, A. G.-H. Jember, H. Akiba, H. Yagita, and M. Croft. 2003. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 198: 315-324.
28. Prlic, M., B. R. Blazar, A. Khoruts, T. Zell, and S. C. Jameson. 2001. Homeostatic expansion occurs independently of costimulatory signals. J. Immunol. 167: 5664-5668.
29. Goldrath, A. W., L. Y. Bogatzki, and M. J. Bevan. 2000. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 192: 557-564.
30. Gao, W., Y. Lu, B. El Essawy, M. Oukka, V. K. Kuchroo, and T. B. Strom. 2007. Contrasting effects of cyclosporine and rapamycin on de novo generation of antigen-specific regulatory T cells. Am. J. Transplant. 7: 1722-1732.